Aging Clinical and Experimental Research

, Volume 10, Issue 4, pp 269–272

Selective estrogen receptor modulators and postmenopausal women’s health: The promise for the next millennium

  • D. Agnusdei


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hammond G.B.: Menopause and hormone replacement therapy: an overview. Obstet. Gynecol. 87: 2–15, 1995.CrossRefGoogle Scholar
  2. 2.
    US Congress, Office of Technology Assessment: Effectiveness and costs of osteoporosis screening and hormone replacement therapy (Vol. II). Evidence of benefits, risks, and costs. US Government printing office, Washington, DC, August 1995.Google Scholar
  3. 3.
    Lindsay R., Aitken J.M., Anderson J.B., Hart D.M., McDonald E.B., Clarke A.C.: Long-term prevention of postmenopausal osteoporosis by estrogen. Evidence for an increased bone mass after delayed onset of estrogen treatment. Lancet I: 1038–1041, 1976.CrossRefGoogle Scholar
  4. 4.
    Compston J.E.: HRT and osteoporosis. Br. Med. Bull. 48: 309, 1992.PubMedGoogle Scholar
  5. 5.
    Felson D.T., Zhang J.T., Hannan M.T., Kiel D.P., Wilson P.W.F., Anderson J.J.: The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329: 1141, 1993.PubMedCrossRefGoogle Scholar
  6. 6.
    Barrett-Connor E., Bush T.L.: Estrogen and coronary heart disease in women. JAMA 265: 1861, 1991.PubMedCrossRefGoogle Scholar
  7. 7.
    Women’s Health Initiative Study Group: Protocol for the clinical trial and observational studies. National Institutes of Health, U.S.A., 1995.Google Scholar
  8. 8.
    The Writing Group for the PEPI trial: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276: 1389–1396, 1996.CrossRefGoogle Scholar
  9. 9.
    The Writing Group for the PEPI trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 273: 199–208, 1995.CrossRefGoogle Scholar
  10. 10.
    Upton G.V.: The perimenopause: physiologic correlates and clinical management. J. Reprod. Med. 27: 1–27, 1982.PubMedGoogle Scholar
  11. 11.
    Beresford S.A., Weiss N.S., Voigt L.F., McKnight B.: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458–461, 1997.PubMedCrossRefGoogle Scholar
  12. 12.
    Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047–1059, 1997.CrossRefGoogle Scholar
  13. 13.
    Sato M., Glasebrook A.L., Bryant H.U.: Raloxifene: a selective estrogen receptor modulator. J. Bone Miner. Metab. 12 (Suppl. 2): S9–S20, 1994.CrossRefGoogle Scholar
  14. 14.
    Black L.J., Sato M., Rowley E.R., Magee D.E., Bekele A., Williams D.C., Cullinan G.J., Bendele R., Kauffman R.F., Bensch W.R., Frolik C.A., Termine J.D., Bryant H.U.: Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93: 63–69, 1994.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Bryant H.U., Dere W.H.: Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc. Soc. Exp. Biol. Med. 217: 45–52, 1998.PubMedCrossRefGoogle Scholar
  16. 16.
    Wakeling A.E., Valcaccia B., Newboult E., Green L.R.: Non-steroidal antioestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J. Steroid Biochem. 20: 111–120, 1984PubMedCrossRefGoogle Scholar
  17. 17.
    Clemens J.A., Bennett D.R., Black L.J., Jones C.D.: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32: 2869–2875, 1983.PubMedCrossRefGoogle Scholar
  18. 18.
    Turner C.H., Sato M., Bryant H.U.: Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135: 2001–2005, 1994.PubMedGoogle Scholar
  19. 19.
    Evans G., Bryant H.U., Magee D., Sato M., Turner R.T.: The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134: 2283–2288, 1994.PubMedGoogle Scholar
  20. 20.
    Heaney R.P., Draper M.W.: Raloxifene and estrogen: comparative bone remodeling kinetics. J. Bone Miner. Res. 9: 1515–1523, 1997.CrossRefGoogle Scholar
  21. 21.
    Delmas P.D., Bjarnason N.H., Mitlak B., Ravoux A.C., Shah A.S., Huster W.J., Draper M., Christiansen C.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337: 1641–1647, 1997.PubMedCrossRefGoogle Scholar
  22. 22.
    Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., Shah A.S., Anderson P.W.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279: 1445–1451, 1998.PubMedCrossRefGoogle Scholar
  23. 23.
    Bjarnason N.H., Haarbo J., Byrjalsen I., Kaufman R.F., Christiansen C.: Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. Circulation 96: 1964–1969, 1997.PubMedCrossRefGoogle Scholar
  24. 24.
    Eastell R.: Treatment of postmenopausal osteoporosis. N. Engl. J. Med. 338: 736–746, 1998.PubMedCrossRefGoogle Scholar
  25. 25.
    Cummings S.R., Norton L., Eckert S., Grady D., Cauley J., Knickerbocker R., Black D.M., Nickelsen T., Glusman G., Krueger K.: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial. Am. Soc. Clin. Oncol. 17: 2a, 1998 (Abstract).Google Scholar
  26. 26.
    Jordan V.C., Glusman J., Eckert S., Lippman M., Powles T., Costa A., Morrow M., Norton L.: Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double blind, randomised trials in 12000 postmenopausal women. Am. Soc. Clin. Oncol. 17: 122a, 1998 (Abstract).Google Scholar

Copyright information

© Springer Internal Publishing Switzerland 1998

Authors and Affiliations

  • D. Agnusdei
    • 1
  1. 1.European Medical Co-ordinator Women’s HealthEli Lilly Italia S.p.A.FirenzeItaly

Personalised recommendations